Drug Profile
Dinutuximab - National Cancer Institute/United Therapeutics Corporation
Alternative Names: Anti-GD2 monoclonal antibody ch14.18; Ch14.18; ch14.18-UTC; Chimeric anti-GD2 monoclonal antibody; OP 08; UnituxinLatest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer National Cancer Institute (USA); New Approaches to Neuroblastoma Therapy Consortium; Ohara Pharmaceutical; St. John of God Foundation; United Therapeutics Corporation
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuroblastoma
- Phase II/III Small cell lung cancer
- Phase II Osteosarcoma
- Discontinued Malignant melanoma
Most Recent Events
- 30 Sep 2023 National Cancer Institute (NCI) completes phase-II clinical trials in Osteosarcoma (Recurrent, Metastatic disease, Second-line therapy or greater) in Puerto Rico, New Zealand, Canada, Australia, USA (IV) (NCT02484443)
- 13 Mar 2023 Launched for Neuroblastoma in Japan (IV) prior to March 2023
- 03 Jun 2022 Initial efficacy and adverse events data from a phase II trial in Neuroblastoma presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)